Salmonella enterica serovar Typhimurium ruvB mutant can confer protection against salmonellosis in mice

Vaccine

Volumn 28, Issue 39, 2010, Pages 6436-6444

  Choi, Jeongjoon ^a   Shin, Dongwoo ^b   Ryu, Sangryeol ^a  

^a Seoul National University   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Live vaccine; RuvB; Salmonellosis

Indexed keywords

BACTERIAL PROTEIN; HELICASE; HYDROGEN PEROXIDE; RUVB PROTEIN; SALMONELLOSIS VACCINE; SPI 2 PROTEIN; SSAG PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; BACTERIAL GENE; BACTERIAL IMMUNITY; BACTERIAL STRAIN; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DELETION MUTANT; DNA REPLICATION; DRUG DOSE COMPARISON; DRUG EFFICACY; EPITHELIUM CELL; FEMALE; GENE DELETION; GENE EXPRESSION; HOLLIDAY JUNCTION; HUMAN; HUMAN CELL; LETHAL DOSE; MACROPHAGE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PATHOGENICITY; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM; SALMONELLOSIS; SINGLE DRUG DOSE; VIRUS VIRULENCE;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; CELL LINE; FEMALE; GENE DELETION; HUMANS; IMMUNOGLOBULIN G; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; OXIDATIVE STRESS; SALMONELLA INFECTIONS, ANIMAL; SALMONELLA TYPHIMURIUM; SALMONELLA VACCINES; VIRULENCE;

EID: 77956419789     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.07.048     Document Type: Article

References (42)

1. Pasquali P., Ammendola S., Pistoia C., Petrucci P., Tarantino M., Valente C., et al. Attenuated Salmonella enterica serovar Typhimurium lacking the ZnuABC transporter confers immune-based protection against challenge infections in mice. Vaccine 2008, 26(June (27-28)):3421-3426.
2. Carvajal B.G., Methner U., Pieper J., Berndt A. Effects of Salmonella enterica serovar Enteritidis on cellular recruitment and cytokine gene expression in caecum of vaccinated chickens. Vaccine 2008, 26(October (42)):5423-5433.
3. Darwin K.H., Miller V.L. Molecular basis of the interaction of Salmonella with the intestinal mucosa. Clin Microbiol Rev 1999, 12(July (3)):405-428.
4. Crump J.A., Luby S.P., Mintz E.D. The global burden of typhoid fever. Bull World Health Organ 2004, 82(May (5)):346-353.
5. Girard M.P., Steele D., Chaignat C.L., Kieny M.P. A review of vaccine research and development: human enteric infections. Vaccine 2006, 24(April (15)):2732-2750.
6. Mastroeni P., Menager N. Development of acquired immunity to Salmonella. J Med Microbiol 2003, 52(June (Pt 6)):453-459.
7. Chuttani C.S., Prakash K., Vergese A., Gupta P., Chawla R.K., Grover V., et al. Ineffectiveness of an oral killed typhoid vaccine in a field trial. Bull World Health Organ 1973, 48(June (6)):754-755.
8. Levine M.M., Ferreccio C., Black R.E., Germanier R. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet 1987, 1(May (8541)):1049-1052.
9. Levine M.M., Tacket C.O., Sztein M.B. Host-Salmonella interaction: human trials. Microbes Infect 2001, 3(November-December (14-15)):1271-1279.
10. Pasetti M.F., Levine M.M., Sztein M.B. Animal models paving the way for clinical trials of attenuated Salmonella enterica serovar Typhi live oral vaccines and live vectors. Vaccine 2003, 21(January (5-6)):401-418.
11. Ivanoff B., Levine M.M., Lambert P.H. Vaccination against typhoid fever: present status. Bull World Health Organ 1994, 72(6):957-971.
12. Cheminay C., Hensel M. Rational design of Salmonella recombinant vaccines. Int J Med Microbiol 2008, 298(January (1-2)):87-98.
13. Negi V.D., Singhamahapatra S., Chakravortty D. Salmonella enterica serovar Typhimurium strain lacking pmrG-HM-D provides excellent protection against salmonellosis in murine typhoid model. Vaccine 2007, 25(July (29)):5315-5323.
14. Tacket C.O., Sztein M.B., Losonsky G.A., Wasserman S.S., Nataro J.P., Edelman R., et al. Safety of live oral Salmonella Typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect Immun 1997, 65(February (2)):452-456.
15. Khan S.A., Stratford R., Wu T., McKelvie N., Bellaby T., Hindle Z., et al. Salmonella Typhi and S. Typhimurium derivatives harbouring deletions in aromatic biosynthesis and Salmonella Pathogenicity Island-2 (SPI-2) genes as vaccines and vectors. Vaccine 2003, 21(January (5-6)):538-548.
16. Kirkpatrick B.D., McKenzie R., O'Neill J.P., Larsson C.J., Bourgeois A.L., Shimko J., et al. Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers. Vaccine 2006, 24(January (2)):116-123.
17. Miller S.I., Loomis W.P., Alpuche-Aranda C., Behlau I., Hohmann E. The PhoP virulence regulon and live oral Salmonella vaccines. Vaccine 1993, 11(2):122-125.
18. Hensel M. Salmonella pathogenicity island 2. Mol Microbiol 2000, 36(June (5)):1015-1023.
19. Parsons C.A., Tsaneva I., Lloyd R.G., West S.C. Interaction of Escherichia coli RuvA and RuvB proteins with synthetic Holliday junctions. Proc Natl Acad Sci USA 1992, 89(June (12)):5452-5456.
20. Donaldson J.R., Courcelle C.T., Courcelle J. RuvABC is required to resolve Holliday junctions that accumulate following replication on damaged templates in Escherichia coli. J Biol Chem 2006, 281(September (39)):28811-28821.
21. Craig M., Slauch J.M. Phagocytic superoxide specifically damages an extracytoplasmic target to inhibit or kill Salmonella. PLoS One 2009, 4(3):e4975.
22. Datsenko K.A., Wanner B.L. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci USA 2000, 97(June (12)):6640-6645.
23. Ellermeier C.D., Janakiraman A., Slauch J.M. Construction of targeted single copy lac fusions using lambda Red and FLP-mediated site-specific recombination in bacteria. Gene 2002, 290(May (1-2)):153-161.
24. Merighi M., Ellermeier C.D., Slauch J.M., Gunn J.S. Resolvase-in vivo expression technology analysis of the Salmonella enterica serovar Typhimurium PhoP and PmrA regulons in BALB/c mice. J Bacteriol 2005, 87(November (21)):7407-7416.
25. Watanabe T., Ogata Y., Chan R.K., Botstein D. Specialized transduction of tetracycline resistance by phage P22 in Salmonella typhimurium. I. Transduction of R factor 222 by phage P22. Virology 1972, 50(December (3)):874-882.
26. Soncini F.C., Vescovi E.G., Groisman E.A. Transcriptional autoregulation of the Salmonella Typhimurium phoPQ operon. J Bacteriol 1995, 177(August (15)):4364-4371.
27. Choi J., Shin D., Ryu S. Implication of quorum sensing in Salmonella enterica serovar Typhimurium virulence: the luxS gene is necessary for expression of genes in pathogenicity island 1. Infect Immun 2007, 75(October (10)):4885-4890.
28. Lim S., Yun J., Yoon H., Park C., Kim B., Jeon B., et al. Mlc regulation of Salmonella pathogenicity island I gene expression via hilE repression. Nucleic Acids Res 2007, 35(6):1822-1832.
29. Miller J.H. Experiments in molecular genetics 1972, Cold Spring Harbor Laboratory Press, Plainview.
30. Coombes B.K., Coburn B.A., Potter A.A., Gomis S., Mirakhur K., Li Y., et al. Analysis of the contribution of Salmonella pathogenicity islands 1 and 2 to enteric disease progression using a novel bovine ileal loop model and a murine model of infectious enterocolitis. Infect Immun 2005, 73(November (11)):7161-7169.
31. Vazquez-Torres A., Xu Y., Jones-Carson J., Holden D.W., Lucia S.M., Dinauer M.C., et al. Salmonella pathogenicity island 2-dependent evasion of the phagocyte NADPH oxidase. Science 2000, 287(March (5458)):1655-1658.
32. Suvarnapunya A.E., Lagasse H.A., Stein M.A. The role of DNA base excision repair in the pathogenesis of Salmonella enterica serovar Typhimurium. Mol Microbiol 2003, 48(April (2)):549-559.
33. Zhang X., Kelly S.M., Bollen W.S., Curtiss R. Characterization and immunogenicity of Salmonella Typhimurium SL1344 and UK-1 delta crp and delta cdt deletion mutants. Infect Immun 1997, 65(December (12)):5381-5387.
34. Jones B.D., Nichols W.A., Gibson B.W., Sunshine M.G., Apicella M.A. Study of the role of the htrB gene in Salmonella Typhimurium virulence. Infect Immun 1997, 65(November (11)):4778-4783.
35. Cirillo D.M., Valdivia R.H., Monack D.M., Falkow S. Macrophage-dependent induction of the Salmonella pathogenicity island 2 type III secretion system and its role in intracellular survival. Mol Microbiol 1998, 30(October (1)):175-188.
36. Coombes B.K., Brown N.F., Valdez Y., Brumell J.H., Finlay B.B. Expression and secretion of Salmonella pathogenicity island-2 virulence genes in response to acidification exhibit differential requirements of a functional type III secretion apparatus and SsaL. J Biol Chem 2004, 279(November (48)):49804-49815.
37. Tacket C.O., Levine M.M. CVD 908, CVD 908-htrA, and CVD 909 live oral typhoid vaccines: a logical progression. Clin Infect Dis 2007, 45(July (Suppl. 1)):S20-S23.
38. Harrison J.A., Villarreal-Ramos B., Mastroeni P., Demarco de Hormaeche R., Hormaeche C.E. Correlates of protection induced by live Aro-Salmonella Typhimurium vaccines in the murine typhoid model. Immunology 1997, 90(April (4)):618-625.
39. Schoenborn J.R., Wilson C.B. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 2007, 96:41-101.
40. Martin-Fontecha A., Thomsen L.L., Brett S., Gerard C., Lipp M., Lanzavecchia A., et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol 2004, 5(December (12)):1260-1265.
41. Eckmann L., Kagnoff M.F. Cytokines in host defense against Salmonella. Microbes Infect 2001, 3(November-December (14-15)):1191-1200.
42. Sack D.A., Sack R.B., Nair G.B., Siddique A.K. Cholera. Lancet 2004, 363(January (9404)):223-233.